Skip to main content
NVDA-2.40%AAPL+2.07%GOOGL+0.03%MSFT-0.04%AMZN+0.20%TSM-0.79%SPCX+2.01%AVGO+0.19%META+0.24%TSLA-0.36%SKHY-3.59%MU-3.98%BRK-B-0.16%LLY+0.62%JPM-0.48%AMD-2.20%WMT+0.12%V-0.23%XOM-0.14%ASMLa-1.48%JNJ-0.16%INTC-3.83%MA-0.51%0700.HK-1.94%ORCL-1.80%1398.HK+0.79%BAC-0.50%ABBV+0.44%CSCO-0.50%CVX-0.61%COST-0.10%LRCX-3.48%KO+0.82%CAT-0.87%AMAT-2.00%0005.HK-0.78%AP2d-1.26%UNH-0.75%DELL-2.68%HSBA.L-1.05%MS-0.15%PG-0.26%GE+0.09%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.20%HD-0.98%GS-0.32%0939.HK+1.66%NZDJPY-2.69%AUDJPY-1.94%CHFJPY-1.66%USDJPY-1.50%GBPJPY-1.39%EURNZD+1.38%EURJPY-1.36%CADJPY-1.36%NZDCAD-1.35%GBPNZD+1.31%NZDUSD-1.23%NZDCHF-1.06%USDNOK+0.94%EURNOK+0.90%CHFNOK+0.82%AUDNZD+0.78%NOKJPY-0.70%USDZAR+0.69%USDSEK+0.67%EURZAR+0.65%EURSEK+0.63%AUDDKK-0.62%AUDCAD-0.61%EURAUD+0.59%GBPZAR+0.55%CHFSEK+0.55%GBPAUD+0.53%AUDSGD-0.50%AUDUSD-0.45%USDMXN+0.43%GBPTRY+0.41%USDTHB+0.41%NZDSGD-0.34%GBPHKD+0.32%EURCHF+0.29%AUDNOK+0.29%GBPMXN-0.28%CADCHF+0.28%AUDCHF-0.28%GBPCHF+0.25%USDPLN+0.23%EURPLN+0.19%USDCHF+0.17%USDILS+0.16%USDSGD+0.15%EURUSD+0.13%USDCAD-0.12%EURSGD+0.12%USDTRY+0.11%GBPUSD+0.10%EURCZK-0.10%NZDMXN-0.09%SGDJPY+0.08%USDCNH+0.05%EURGBP+0.05%EURHKD-0.05%GBPCAD-0.05%USDCOP-0.04%EURCNH+0.04%CHFSGD+0.04%USDDKK+0.03%GBPSGD+0.02%PLNJPY+0.01%USDHKD+0.01%EURDKK0.00%EURCAD0.00%XPTUSD-4.76%HG1-4.48%GAGUSD-4.14%XAGUSD-4.14%UKOIL+3.50%USOIL+3.10%SUGAR+1.64%GAUUSD-0.92%XAUUSD-0.92%COTTON+0.71%S1+0.63%COFFEE-0.56%BTCUSD-1.22%ETHUSD-1.04%USDTUSD-0.02%XRPUSD-2.61%SOLUSD-1.44%TRXUSDT0.00%ZECUSDT-5.72%DOGEUSD-2.86%XMRUSDT-1.69%LINKUSD-1.08%XLMUSD-1.94%BCHUSDT-10.58%LTCUSD-1.72%UNIUSD-3.41%TONUSD+24.88%HBARUSDT-1.87%SUIUSD-3.40%TAOUSDT-5.14%AAVEUSD-2.85%DOTUSDT-3.61%ICPUSDT-0.90%ONDOUSDT-2.84%WLDUSDT-2.67%ATOMUSDT-3.41%ARBUSDT+1.37%JUPUSDT-2.96%INJUSDT-4.87%STXUSDT-3.07%FETUSDT-3.62%TIAUSDT-0.87%PYTHUSDT-0.07%SEIUSDT-3.91%IMXUSDT-3.85%GRTUSDT-2.94%WIFUSDT-4.89%OPUSDT-3.00%IOTAUSDT-3.86%POLUSDT-5.76%AXSUSDT-2.47%FARTCOINUSDT-2.74%EOSUSDT-0.68%DYDXUSDT-0.71%ORDIUSDT-0.85%GALAUSDT-4.78%NOTUSDT-2.97%RONINUSDT-2.64%NVDA-2.40%AAPL+2.07%GOOGL+0.03%MSFT-0.04%AMZN+0.20%TSM-0.79%SPCX+2.01%AVGO+0.19%META+0.24%TSLA-0.36%SKHY-3.59%MU-3.98%BRK-B-0.16%LLY+0.62%JPM-0.48%AMD-2.20%WMT+0.12%V-0.23%XOM-0.14%ASMLa-1.48%JNJ-0.16%INTC-3.83%MA-0.51%0700.HK-1.94%ORCL-1.80%1398.HK+0.79%BAC-0.50%ABBV+0.44%CSCO-0.50%CVX-0.61%COST-0.10%LRCX-3.48%KO+0.82%CAT-0.87%AMAT-2.00%0005.HK-0.78%AP2d-1.26%UNH-0.75%DELL-2.68%HSBA.L-1.05%MS-0.15%PG-0.26%GE+0.09%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.20%HD-0.98%GS-0.32%0939.HK+1.66%NZDJPY-2.69%AUDJPY-1.94%CHFJPY-1.66%USDJPY-1.50%GBPJPY-1.39%EURNZD+1.38%EURJPY-1.36%CADJPY-1.36%NZDCAD-1.35%GBPNZD+1.31%NZDUSD-1.23%NZDCHF-1.06%USDNOK+0.94%EURNOK+0.90%CHFNOK+0.82%AUDNZD+0.78%NOKJPY-0.70%USDZAR+0.69%USDSEK+0.67%EURZAR+0.65%EURSEK+0.63%AUDDKK-0.62%AUDCAD-0.61%EURAUD+0.59%GBPZAR+0.55%CHFSEK+0.55%GBPAUD+0.53%AUDSGD-0.50%AUDUSD-0.45%USDMXN+0.43%GBPTRY+0.41%USDTHB+0.41%NZDSGD-0.34%GBPHKD+0.32%EURCHF+0.29%AUDNOK+0.29%GBPMXN-0.28%CADCHF+0.28%AUDCHF-0.28%GBPCHF+0.25%USDPLN+0.23%EURPLN+0.19%USDCHF+0.17%USDILS+0.16%USDSGD+0.15%EURUSD+0.13%USDCAD-0.12%EURSGD+0.12%USDTRY+0.11%GBPUSD+0.10%EURCZK-0.10%NZDMXN-0.09%SGDJPY+0.08%USDCNH+0.05%EURGBP+0.05%EURHKD-0.05%GBPCAD-0.05%USDCOP-0.04%EURCNH+0.04%CHFSGD+0.04%USDDKK+0.03%GBPSGD+0.02%PLNJPY+0.01%USDHKD+0.01%EURDKK0.00%EURCAD0.00%XPTUSD-4.76%HG1-4.48%GAGUSD-4.14%XAGUSD-4.14%UKOIL+3.50%USOIL+3.10%SUGAR+1.64%GAUUSD-0.92%XAUUSD-0.92%COTTON+0.71%S1+0.63%COFFEE-0.56%BTCUSD-1.22%ETHUSD-1.04%USDTUSD-0.02%XRPUSD-2.61%SOLUSD-1.44%TRXUSDT0.00%ZECUSDT-5.72%DOGEUSD-2.86%XMRUSDT-1.69%LINKUSD-1.08%XLMUSD-1.94%BCHUSDT-10.58%LTCUSD-1.72%UNIUSD-3.41%TONUSD+24.88%HBARUSDT-1.87%SUIUSD-3.40%TAOUSDT-5.14%AAVEUSD-2.85%DOTUSDT-3.61%ICPUSDT-0.90%ONDOUSDT-2.84%WLDUSDT-2.67%ATOMUSDT-3.41%ARBUSDT+1.37%JUPUSDT-2.96%INJUSDT-4.87%STXUSDT-3.07%FETUSDT-3.62%TIAUSDT-0.87%PYTHUSDT-0.07%SEIUSDT-3.91%IMXUSDT-3.85%GRTUSDT-2.94%WIFUSDT-4.89%OPUSDT-3.00%IOTAUSDT-3.86%POLUSDT-5.76%AXSUSDT-2.47%FARTCOINUSDT-2.74%EOSUSDT-0.68%DYDXUSDT-0.71%ORDIUSDT-0.85%GALAUSDT-4.78%NOTUSDT-2.97%RONINUSDT-2.64%
SA

Savara Inc. (SVRA)

NASDAQ • Healthcare

$5.42
-$0.11 (-2.0%)
Market open

Last close at September 9, 2026 at 20:00 UTC

Open$5.48
Previous Close$5.42
Day Range$5.37 - $5.57
Avg. Volume (3M)1.5M
Market Cap$1.1B
52 Week Range
$3.34$7.01
Next EarningsIn 62 daysNov 11, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$139.3M
EPS (TTM)
-$0.58
ROA (TTM)
-72.5%
Current Ratio
10.13
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-8.3%Q1 2026-$0.13
-7.1%Q2 2026-$0.15
-13.3%Q3 2026-$0.16
Next

Nov 11

in 62 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -13.3%

Savara’s loss per share trailed consensus in the second fiscal quarter of 2026, based on preliminary results reported August 11, 2026, with EPS of -$0.16 trailing the -$0.14 estimate (difference -$0.02) and down from -$0.14 a year ago. The biotech, which is centered on its molgramostim program for uncommon respiratory conditions, posted GAAP net income of roughly -$40.2 million, a wider loss (net_income YoY -32.3%) versus about -$30.4 million a year earlier, alongside GAAP operating income of around -$41.0 million. Cash burn remained visible, with negative operating cash flow of about -$29.7 million during the quarter, and the company repurchased about $0.0 million of stock. Looking ahead, next-period consensus calls for EPS of -$0.16 on revenue of $500,000.00.

View full earnings history

About Savara Inc.

Savara Inc. is a NASDAQ-listed Biotechnology company focused on medicines for uncommon respiratory conditions. The company centers its work on molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor, and it operates as a small-cap developer rather than a commercial diversified drugmaker.

Name
Savara Inc.
CEO
Matthew Pauls
Website
www.savarapharma.com
Industry
Healthcare
Employees
70

Today's Snapshot

AI-generated

SVRA opened 1.4% below yesterday's close, while its sector was flat.

Trading Volume

Below 10d avg (1.2M)

359.1K

vs S&P 500 Today

Underperforming Market

-1.38%

Updated: September 10, 2026 at 14:41 UTC

Technical Indicators

0 Buy2 Neutral6 Sell
The technical picture for SVRA is biased strongly negative, driven by weakening momentum and pervasive moving‑average pressure. Momentum indicators are soft — RSI in the mid‑40s with MACD below zero and short‑term momentum negative — while most short and medium moving averages sit above the current price and the 200‑day average also exceeds the market, reinforcing downside bias. ADX near 11.6 indicates a lack of trend conviction, and ATR around 4.35% shows moderate intraday range. Volume‑based OBV shows some accumulation but is outweighed by multiple sell signals and the pivot at 5.45 remaining above price. Technical takeaway: strong sell.
All signals
  • EMA (5 indicators)$5.32 - $5.51
    Sell
  • RSI (14)43.66
    Neutral
  • Stochastic %K (14, 3, 3)40.03
    Neutral
  • MACD Level (12, 26)-0.05
    Sell

Peers & Related Assets

TNGXTango Therapeutics, Inc.
$24+5.7%
BCAXBicara Therapeutics Inc. Common Stock
$23.64-0.3%
TYRATyra Biosciences, Inc.
$22.01-17.7%
KURAKura Oncology, Inc.
$12.09-3.4%
GERNGeron Corporation
$1.4-7.3%
EYPTEyePoint Pharmaceuticals, Inc.
$4.34-4.8%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.